Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

3selected

Field	CLOPIDOGREL Haematology · Haematology · Level 2	ABCIXIMAB Haematology · Haematology · Level 3	TIROFIBAN Haematology · Haematology · Level 3
Mechanism of action	Prodrug. Hepatic activation to active agent (Thiol derivative, by oxidation and hydrolysis) which is an ADP receptor antagonist - Irreversible inhibition of P2Y12 receptor at platelet surface → Inhibits activation of GPIIb/IIIa → Inhibits platelet activation	Similar mechanism as tirofiban but monoclonal antibody	Antagonises the GpIIb/IIIa receptor, preventing the binding of fibrinogen and platelet crosslinking and aggregation.
Absorption	- PO. BA 50% - 600mg loading. 75mg maint.	—	—
Protein binding	95% protein binding,	—	—
Volume of distribution	Vd unknown	—	—
Metabolism	- Hepatic CYP450 2C19 + Esterases to Inactive metab	Platelet function typically returns to normal 24-48 hours after infusion ceases	Limited metabolism in humans.
Excretion	- Renal and faecal elimination	Platelet function typically returns to normal 24-48 hours after infusion ceases	Excreted in urine and faeces, mostly unchanged
Half-life	- T1/2b 7 hours parent drug (30mins metab) Dur: life of platelet	—	HL 1.9-2.2 hrs
Adverse Effects Toxicity	Bleeding TTP Agranulocytosis, Neutropenia Significant drug interactions as requires activation by CYP450	Haemorrhage, thrombocytopenia, human antichimeric antibody development, allergic reaction	Haemorrhage Difficulty reversing agent Dose adjustment in renal impairment
Class Group	Antiplatelet	Antiplatelet	Antiplatelet
Introduction	ADP Receptor Antagonist - Thienopyridine	GP IIb/IIIA Inhibitor	GP IIb/IIIA Inhibitor
Legacy Cicm Level	Level 3	Level 3	Level 3
Main Action	Platelet inhibition	Platelet inhibition	Platelet inhibition